Hepatic, Intestinal, Renal, and Plasma Hydrolysis of Prodrugs in Human, Cynomolgus Monkey, Dog, and Rat: Implications for In Vitro–In Vivo Extrapolation of Clearance of Prodrugs

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Drug Metabolism And Disposition

• Publication date

  2014-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/dmd.114.057372PMID 24994071
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Human in vivo regional intestinal permeability: importance for pharmaceutical drug development.

  2014influential reference
• Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue.

  2013cited by this paper
• The Role of Human Carboxylesterases in Drug Metabolism: Have We Overlooked Their Importance?

  2013influential reference
• Different Hydrolases Involved in Bioactivation of Prodrug-Type Angiotensin Receptor Blockers: Carboxymethylenebutenolidase and Carboxylesterase 1

  2013influential reference
• Comparison of Oseltamivir and Oseltamivir Carboxylate Concentrations in Venous Plasma, Venous Blood, and Capillary Blood in Healthy Volunteers

  2013cited by this paper
• Characterization of In Vitro Glucuronidation Clearance of a Range of Drugs in Human Kidney Microsomes: Comparison with Liver and Intestinal Glucuronidation and Impact of Albumin

  2012influential reference
• The emerging role of human esterases.

  2012cited by this paper
• Simultaneous Absolute Protein Quantification of Carboxylesterases 1 and 2 in Human Liver Tissue Fractions using Liquid Chromatography-Tandem Mass Spectrometry

  2012cited by this paper
• Species difference of esterase expression and hydrolase activity in plasma.

  2012cited by this paper
• Paraoxonase 1 as a Major Bioactivating Hydrolase for Olmesartan Medoxomil in Human Blood Circulation: Molecular Identification and Contribution to Plasma Metabolism

  2012cited by this paper
• Targeted prodrugs in oral drug delivery: the modern molecular biopharmaceutical approach

  2012cited by this paper
• Prodrugs—from Serendipity to Rational Design

  2011cited by this paper
• Prediction of the intestinal first-pass metabolism of CYP3A and UGT substrates in humans from in vitro data.

  2011cited by this paper
• Characterization of the Expression and Activity of Carboxylesterases 1 and 2 from the Beagle Dog, Cynomolgus Monkey, and Human

  2011influential reference
• Effect of milk on the pharmacokinetics of oseltamivir in healthy volunteers.

  2011cited by this paper
• Enhanced Antihypertensive Activity of Candesartan Cilexetil Nanosuspension: Formulation, Characterization and Pharmacodynamic Study

  2011influential reference
• Prediction of Human Drug Clearance by Multiple Metabolic Pathways: Integration of Hepatic and Intestinal Microsomal and Cytosolic Data

  2011cited by this paper
• Genomic analysis of the carboxylesterases: identification and classification of novel forms.

  2010cited by this paper
• The role of intestinal carboxylesterase in the oral absorption of prodrugs.

  2010influential reference
• Prodrugs: Some thoughts and current issues.

  2010cited by this paper
• Human Carboxymethylenebutenolidase as a Bioactivating Hydrolase of Olmesartan Medoxomil in Liver and Intestine

  2010cited by this paper
• Involvement of Carboxylesterase 1 and 2 in the Hydrolysis of Mycophenolate Mofetil

  2010cited by this paper
• Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data

  2010influential reference
• Prediction of Human Metabolic Clearance from In Vitro Systems: Retrospective Analysis and Prospective View

  2010cited by this paper
• Prediction of Drug Clearance by Glucuronidation from in Vitro Data: Use of Combined Cytochrome P450 and UDP-Glucuronosyltransferase Cofactors in Alamethicin-Activated Human Liver Microsomes

  2009influential reference
• Esterase activities in the blood, liver and intestine of several preclinical species and humans.

  2009cited by this paper
• Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches

  2009cited by this paper
• Relative Importance of Intestinal and Hepatic Glucuronidation—Impact on the Prediction of Drug Clearance

  2009cited by this paper
• Methods for predicting in vivo pharmacokinetics using data from in vitro assays.

  2008influential reference
• Regulation of Drug-Metabolizing Enzymes and Transporters in Infection, Inflammation, and Cancer

  2008cited by this paper
• Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting.

  2008cited by this paper
• Structure and Catalytic Properties of Carboxylesterase Isozymes Involved in Metabolic Activation of Prodrugs

  2008influential reference
• Hepatocellular Binding of Drugs: Correction for Unbound Fraction in Hepatocyte Incubations Using Microsomal Binding or Drug Lipophilicity Data

  2008cited by this paper
• Carboxylesterase in the liver and small intestine of experimental animals and human.

  2007influential reference
• Human carboxylesterase isozymes: catalytic properties and rational drug design.

  2006cited by this paper
• BINDING OF DRUGS TO HEPATIC MICROSOMES: COMMENT AND ASSESSMENT OF CURRENT PREDICTION METHODOLOGY WITH RECOMMENDATION FOR IMPROVEMENT

  2006cited by this paper
• THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”

  2006cited by this paper
• Intestinal and Hepatic Metabolic Activity of Five Cytochrome P450 Enzymes: Impact on Prediction of First-Pass Metabolism

  2006cited by this paper
• Hydrolysis of Capecitabine to 5′-Deoxy-5-fluorocytidine by Human Carboxylesterases and Inhibition by Loperamide

  2005cited by this paper
• Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma.

  2005cited by this paper
• Current progress on esterases: from molecular structure to function.

  2002cited by this paper
• Species Differences in Stereoselective Hydrolase Activity in Intestinal Mucosa

  1998cited by this paper
• Isolation and pharmacological characterization of microsomal human liver flumazenil carboxylesterase.

  1998cited by this paper
• Single dose and steady state pharmacokinetics of temocapril and temocaprilat in young and elderly hypertensive patients.

  1998cited by this paper
• The mammalian carboxylesterases: from molecules to functions.

  1998cited by this paper
• Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells.

  1996cited by this paper
• Pharmacokinetics, metabolism and biliary and urinary excretion of oral ramipril in man.

  1995cited by this paper
• Trandolapril: Pharmacokinetics of Single Oral Doses in Healthy Male Volunteers

  1994cited by this paper
• Study on pharmacokinetics of a new biliary excreted oral angiotensin converting enzyme inhibitor, temocapril (CS‐622) in humans

  1993cited by this paper
• Pharmacokinetics of perindopril and its metabolites in healthy volunteers

  1990cited by this paper
• The Clinical Pharmacokinetics of Quinapril

  1989cited by this paper
• Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril.HCl (CGS 14 824 A) in healthy volunteers after single and repeated administration.

  1989cited by this paper
• The pharmacokinetics and bioavailability of cilazapril in normal man.

  1989cited by this paper
• Influence of renal function on the pharmacokinetics of ramipril (HOE 498).

  1987cited by this paper
• Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance

  1977cited by this paper

• Characterization of small molecule drug clearance mechanisms using in vitro and in vivo approaches in drug discovery and development

  2025cites this paper
• Human and rat renal proximal tubule in vitro models for ADME applications

  2025cites this paper
• Single-Dose Oral Influenza Antiviral Prodrug Enabled by Cholesterol Conjugation.

  2025cites this paper
• Prediction of human pharmacokinetics of procymidone and its major phase I and II metabolites using a PBPK model with enterohepatic circulation.

  2025cites this paper
• Target Cell Activation of a Structurally Novel NOD-Like Receptor Pyrin Domain-Containing Protein 3 Inhibitor NT-0796 Enhances Potency

  2024cites this paper
• Simultaneously Predicting the Pharmacokinetics of CES1-Metabolized Drugs and Their Metabolites Using Physiologically Based Pharmacokinetic Model in Cirrhosis Subjects

  2024cites this paper
• Interspecies comparison of metabolism of two novel prototype PFAS.

  2024cites this paper
• Novel approach for verification of a human PBPK modeling strategy using chimeric mice in the health risk assessment of epyrifenacil.

  2023cites this paper
• Developing an adult stem cell derived microphysiological intestinal system for predicting oral prodrug bioconversion and permeability in humans.

  2023cites this paper
• p53-responsive CMBL reprograms glucose metabolism and suppresses cancer development by destabilizing phosphofructokinase PFKP.

  2023cites this paper
• Metabolism Characterization and Chemical and Plasma Stability of Casearin B and Caseargrewiin F

  2023cites this paper
• Utility of a Systematic Approach to Selecting Candidate Prodrugs: A Case Study Using Candesartan Ester Analogues.

  2023cites this paper
• Prediction of the human pharmacokinetics of epyrifenacil and its major metabolite, S-3100-CA, by a physiologically based pharmacokinetic modeling using chimeric mice with humanized liver.

  2022cites this paper
• A physiologically based pharmacokinetic and pharmacodynamic model for disposition of FF-10832.

  2022cites this paper
• Application of a gut-liver-on-a-chip device and mechanistic modelling to the quantitative in vitro pharmacokinetic study of mycophenolate mofetil.

  2022cites this paper
• Design and synthesis of water-soluble prodrugs of rifabutin for intraveneous administration.

  2022cites this paper
• Stereoselective Metabolism of Bupropion to Active Metabolites in Cellular Fractions of Human Liver and Intestine

  2022influential citation
• Bottom-up physiologically based pharmacokinetic modelling for predicting the human pharmacokinetic profiles of the ester prodrug MGS0274 and its active metabolite MGS0008, a metabotropic glutamate 2/3 receptor agonist

  2022influential citation
• Evaluation of anti-inflammatory, immunomodulatory effects and celiac-like side effect of olmesartan medoxomil as a vitamin D receptor agonist and angiotensin II receptor blocker

  2022cites this paper
• Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions.

  2021cites this paper
• Metabolism and Interspecies Variation of IMMH-010, a Programmed Cell Death Ligand 1 Inhibitor Prodrug

  2021cites this paper
• Investigating the glucuronidation and sulfation pathways contribution and disposition kinetics of Bisphenol S and its metabolites using LC-MS/MS-based nonenzymatic hydrolysis method.

  2021cites this paper
• Design, synthesis and antihypertensive evaluation of novel codrugs with combined angiotensin type 1 receptor antagonism and neprilysin inhibition.

  2021cites this paper
• Physiologically based pharmacokinetic modeling of candesartan related to CYP2C9 genetic polymorphism in adult and pediatric patients

  2021cites this paper
• Prediction of Drug Clearance from Enzyme and Transporter Kinetics.

  2021cites this paper
• Recent developments in predicting CYP-independent metabolism

  2021cites this paper
• In Vitro Hepatic Metabolism of Curcumin Diethyl Disuccinate by Liver S9 from Different Animal Species

  2020cites this paper
• Evaluation of In Vitro Models for Assessment of Human Intestinal Metabolism in Drug Discovery

  2020cites this paper
• Discovery of MGS0274, an ester prodrug of a metabotropic glutamate receptor 2/3 agonist with improved oral bioavailability.

  2020cites this paper
• In Vitro, In Silico, and In Vivo Assessments of Pharmacokinetic Properties of ZM241385

  2020cites this paper
• Metabolism and Pharmacokinetics of SP-8356, a Novel (1S)-(−)-Verbenone Derivative, in Rats and Dogs and Its Implications in Humans

  2020cites this paper
• CHARACTERIZATION OF DIFFERENTIAL TISSUE ABUNDANCE OF MAJOR NON-CYP ENZYMES IN HUMAN.

  2020cites this paper
• Strain and sex differences in drug hydrolase activities in rodent livers.

  2019cites this paper
• L‐type amino acid transporter 1 utilizing prodrugs of ferulic acid revealed structural features supporting the design of prodrugs for brain delivery

  2019cites this paper
• Mouse Pharmacokinetics and in Vitro Metabolism of (±)-Cremastranone.

  2019cites this paper
• Utility of Chimeric Mice with Humanized Liver for Predicting Human Pharmacokinetics in Drug Discovery: Comparison with in Vitro-in Vivo Extrapolation and Allometric Scaling.

  2019cites this paper
• Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling

  2019cites this paper
• The Impact of Carboxylesterases in Drug Metabolism and Pharmacokinetics

  2018cites this paper
• The expanding role of prodrugs in contemporary drug design and development

  2018cites this paper
• Pharmacokinetics and Metabolism of Streptochlorin and Its Synthetic Derivative, 5-Hydroxy-2'-isobutyl Streptochlorin, in Mice.

  2018cites this paper
• Difference in substrate specificity of carboxylesterase and arylacetamide deacetylase between dogs and humans

  2018cites this paper
• Microsomal and Cytosolic Scaling Factors in Dog and Human Kidney Cortex and Application for In Vitro-In Vivo Extrapolation of Renal Metabolic Clearance

  2017cites this paper
• Age-Dependent Absolute Abundance of Hepatic Carboxylesterases (CES1 and CES2) by LC-MS/MS Proteomics: Application to PBPK Modeling of Oseltamivir In Vivo Pharmacokinetics in Infants

  2017cites this paper
• Integrated Lead Optimization: Translational Models as We Advance Toward the Clinic

  2017cites this paper
• HALO- AND SOLVATO-FLUOROCHROMIC POLYMER NANOASSEMBLIES FOR CANCER THERANOSTICS

  2017cites this paper
• Identification of esterase involved in the metabolism of two corticosteroid soft drugs

  2017cites this paper
• Optimization of intestinal microsomal preparation in the rat: A systematic approach to assess the influence of various methodologies on metabolic activity and scaling factors

  2017cites this paper
• Tissue distribution of capilliposide B, capilliposide C and their bioactive metabolite in mice using liquid -tandem mass spectrometry.

  2017cites this paper
• Comparative metabolism of DDAO benzoate in liver microsomes from various species.

  2017cites this paper
• In Vitro-In Vivo Extrapolation of Intestinal Availability for Carboxylesterase Substrates Using Portal Vein-Cannulated Monkey.

  2017cites this paper
• Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWG.

  2016cites this paper
• Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions—an Industry Perspective

  2016cites this paper
• Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models

  2016cites this paper
• Caracterização in vitro do metabolismo e da absorção intestinal da casearina X

  2016cites this paper
• Paraoxonases-1, -2 and -3: What are their functions?

  2016cites this paper
• Development of a novel sectional multiple filtering scheme for rapid screening and classifying metabolites of ziyuglycoside II in rat liver and excreta specimen based on high-resolution mass spectrometry.

  2016cites this paper
• Physiological scaling factors and mechanistic models for prediction of renal clearance from in vitro data

  2016influential citation
• Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination

  2016cites this paper
• Enhancement of dissolution rate and intestinal stability of candesartan cilexitil

  2016cites this paper
• Tissue-infiltrating plasma cells are an important source of carboxylesterase 2 contributing to the therapeutic efficacy of prodrugs.

  2016cites this paper
• A Comparison of Non-Human Primate Cytochrome P450 2D Members and the Implication in Drug Discovery.

  2016cites this paper
• Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance

  2016cites this paper
• Key to Opening Kidney for In Vitro–In Vivo Extrapolation Entrance in Health and Disease: Part I: In Vitro Systems and Physiological Data

  2016cites this paper
• Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part II: Mechanistic Models and In Vitro-In Vivo Extrapolation

  2016cites this paper
• Nonhuman Primate Self-Administration in Assessments of Abuse Potential

  2015cites this paper
• Phase II Metabolism in Human Skin: Skin Explants Show Full Coverage for Glucuronidation, Sulfation, N-Acetylation, Catechol Methylation, and Glutathione Conjugation

  2015cites this paper
• P-glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain Disposition and Oral Availability of the Novel Taxane Cabazitaxel (Jevtana) in Mice.

  2015cites this paper
• DMD060350 126..139

  2014influential citation